Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment DMX-200 is in a pivotal Phase 3 trial for ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.Results from the ESSENCE phase 3 clinical trial ...

Tresidder said his Melbourne-based firm has “a real focus” on biotech and life sciences. He sketched some of the ways brokers ...

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy ...

Palvella Therapeutics, Inc.’s PVLA share price has dipped by 8.38%, which has investors questioning if this is right time to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...